Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1046 results
July 2016
-
Media ReleaseNovartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospectsQ2 net sales were flat (0% cc[1]) as Growth Products[2] offset Gleevec generic impact Gilenya (USD 811 million, +17% cc) continued to grow double-digit mainly due to volume growth Cosentyx (…
-
Media ReleaseAlcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopiaPresbyopia is an eye condition that is part of natural aging affecting nearly 2 billion people worldwide.[1] Dailies Total1® Multifocal contact lenses provide a seamless visual experience…
-
Media ReleaseSandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseasesCommittee votes unanimously in favor of the Sandoz proposed biosimilar etanercept for all approved indications of the reference product …
-
Media ReleaseNew data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator productThe EGALITY study met its primary endpoint demonstrating equivalent efficacy of Sandoz biosimilar etanercept candidate to the originator product at week 12 As a first-of-its kind, the…
June 2016
-
Media ReleaseNovartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM)In the largest and longest-running prospective trial in advanced SM, 60% of patients achieved complete or partial resolution of organ damage[1] Advanced SM is rare and has a poor prognosis[…
-
Media ReleaseLargest global psoriasis survey shows 84% of people face discrimination and humiliation because of their skinGlobal survey of over 8,300 people with moderate-to-severe psoriasis is the first to look at perceptions of clear skin[1] Nearly half (45%) have been asked if they are contagious while 55% do not…
-
Media ReleaseNovartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with XencorAgreement is the latest in a series of acquisitions and strategic collaborations that have bolstered Novartis' deep and diverse immuno-oncology pipeline Collaboration will co-develop Xencor's…
-
Media ReleaseTimely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA CardiologyFindings are first to quantify magnitude of potential survival benefits if Entresto were prescribed to all eligible US HFrEF patients (as defined by authors) [1] Cardiology experts…
-
Media ReleaseNovartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatmentNovartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates…
-
Media ReleaseNovartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytopenia, a rare blood disorderEXTEND study provides long-term safety data for Revolade that are consistent with the findings from the pivotal Phase III RAISE study[1,2] Immune thrombocytopenia (ITP) is a rare and potentially…
-
Media ReleaseNovartis presents data showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV)Three times as many patients with inadequately controlled PV without enlarged spleen had hematocrit control without phlebotomy on Jakavi® (ruxolitinib) vs BAT[1] RESPONSE-2 complements data…
Pagination
- ‹ Previous page
- 1
- …
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- …
- 88
- › Next page